Today: 2 July 2026
Browse Category

NYSE:LLY 30 December 2025 - 7 January 2026

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

New York, Jan 6, 2026, 11:34 AM EST — Regular session Arrowhead Pharmaceuticals shares rose about 16% on Tuesday after early clinical data showed its experimental gene-silencing obesity drug boosted weight loss when used alongside Eli Lilly’s tirzepatide, sold as Zepbound. The stock was up 16% at $74.13 in midday trading, after swinging between $62.17 and $76.32. Investors.com
6 January 2026
···
Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

New York, January 6, 2026, 10:55 EST — Regular session Eli Lilly and Company shares rose about 1.6% on Tuesday after Nimbus Therapeutics announced a research and licensing agreement with the drugmaker aimed at developing an oral obesity treatment. Lilly was trading at $1,057.80 in New York morning trade, after moving between $1,040.15 and $1,070.77 earlier in the session. Reuters
6 January 2026
··
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

New York, January 5, 2026, 14:21 EST — Regular session Shares of Viking Therapeutics slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%.
5 January 2026
·····
Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, according to data from healthcare research firm 3 Axis Advisors. The median increase is about 4%, and the figures do not reflect rebates or other discounts. The same dataset showed drugmakers also plan to cut list prices on about nine medicines, including a more than 40% reduction for diabetes drug Jardiance, sold by Boehringer Ingelheim and Eli Lilly, after Medicare negotiated a lower price for 2026. Reuters For investors, that is the opening backdrop for the Eli Lilly stock forecast in 2026: strong demand drivers on one side, widening political and commercial pressure on drug pricing on the other.
1 January 2026
··
1 … 5 6 7 8 9 … 13

Stock Market Today

  • Petrobras Tweaks Diesel Prices, Keeps Distributor Rate Flat
    July 2, 2026, 9:50 AM EDT. Petrobras has updated its diesel pricing for distributors, cutting the list price by 0.3515 reais per liter from July 1, but at the same time scrapping a temporary 0.3515 discount. The end result: distributors still pay an average 3.30 reais per liter. The company wants to stay responsive to market moves but avoid shaking up the distribution chain. This adjustment lands as the Brazilian government moves ahead with plans to drop a 0.35 reais per liter diesel subsidy tied to earlier pandemic policies.
Go toTop